FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:601-608 February 13, 2003 Number 7 Next

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of these antibodies in patients with Crohn's disease.

Methods In a cohort of 125 consecutive patients with Crohn's disease who were treated with infliximab infusions, we evaluated the concentrations of infliximab and of antibodies against infliximab, clinical data, side effects (including infusion reactions), and the use of concomitant medications before and 4, 8, and 12 weeks after each infusion.

Results A mean of 3.9 infusions (range, 1 to 17) per patient were administered over a mean period of 10 months. Antibodies against infliximab were detected in 61 percent of patients. The presence of concentrations of 8.0 µg per milliliter or greater before an infusion predicted a shorter duration of response (35 days, as compared with 71 days among patients with concentrations of less than 8.0 µg per milliliter; P<0.001) and a higher risk of infusion reactions (relative risk, 2.40; 95 percent confidence interval, 1.65 to 3.66; P<0.001). Infliximab concentrations were significantly lower at four weeks among patients who had had an infusion reaction than among patients who had never had an infusion reaction (median, 1.2 vs. 14.1 µg per milliliter; P<0.001). Patients who had infusion reactions had a median duration of clinical response of 38.5 days, as compared with 65 days among patients who did not have an infusion reaction (P<0.001). Concomitant immunosuppressive therapy was predictive of low titers of antibodies against infliximab (P<0.001) and high concentrations of infliximab four weeks after an infusion (P<0.001).

Conclusions The development of antibodies against infliximab is associated with an increased risk of infusion reactions and a reduced duration of response to treatment. Concomitant immunosuppressive therapy reduces the magnitude of the immunogenic response.

Source Information

From the Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg (F.B., M.N., S.V., G.V.A., G.D., P.R.); and the University Center for Statistics, Leuven University (A.C.) — both in Leuven, Belgium.

Address reprint requests to Dr. Rutgeerts at the Department of Internal Medicine, UZ Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium, or at paul.rutgeerts{at}uz.kuleuven.ac.be.

Full Text of this Article

Related Letters:

Immunogenicity of Infliximab in Crohn's Disease
Hanauer S. B., Rutgeerts P., Baert F., Noman M.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:2155-2156, May 22, 2003. Correspondence

This article has been cited by other articles:

• de Vries, M K, Brouwer, E, van der Horst-Bruinsma, I E, Spoorenberg, A, van Denderen, J C, Jamnitski, A, Nurmohamed, M T, Dijkmans, B A C, Aarden, L A, Wolbink, G J (2009). Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68: 1787-1788 [Full Text]  
• Fidder, H, Schnitzler, F, Ferrante, M, Noman, M, Katsanos, K, Segaert, S, Henckaerts, L, Van Assche, G, Vermeire, S, Rutgeerts, P (2009). Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58: 501-508 [Abstract] [Full Text]  
• van den Bemt, B J F, den Broeder, A A, Snijders, G F, Hekster, Y A, van Riel, P L C M, Benraad, B, Wolbink, G J, van den Hoogen, F H J (2008). Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Ann Rheum Dis 67: 1697-1701 [Abstract] [Full Text]  
• Albert, D, Dunham, J, Khan, S, Stansberry, J, Kolasinski, S, Tsai, D, Pullman-Mooar, S, Barnack, F, Striebich, C, Looney, R J, Prak, E T L., Kimberly, R, Zhang, Y, Eisenberg, R (2008). Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67: 1724-1731 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Massey, D C O, Bredin, F, Parkes, M (2008). Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 57: 1294-1296 [Abstract] [Full Text]  
• Li, E. K., Griffith, J. F., Lee, V. W., Wang, Y.-X., Li, T. K., Lee, K. K., Tam, L.-S. (2008). Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 47: 1358-1363 [Abstract] [Full Text]  
• Hinojosa, J., Borras-Blasco, J., Maroto, N., Rosique-Robles, J D., Alos, R., Castera, M. E. (2008). Severe Myalgia Associated with Adalimumab Treatment in a Patient with Crohn's Disease. The Annals of Pharmacotherapy 42: 1130-1133 [Abstract] [Full Text]  
• Van, L., Modi, S. V., Yang, D. J., Hsu, S. (2008). Sustained Efficacy and Safety of Adalimumab in Psoriasis Treatment: A Retrospective Study of 49 Patients With and Without a History of TNF-{alpha} Antagonist Treatment. Arch Dermatol 144: 804-806 [Full Text]  
• Roblin, X., Phelip, J. M. (2008). Risks of Combining Immunosuppressive and Biological Treatments in Inflammatory Bowel Disease. Arch Intern Med 168: 667-667 [Full Text]  
• Kristensen, L E, Gulfe, A, Saxne, T, Geborek, P (2008). Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 67: 364-369 [Abstract] [Full Text]  
• Svenson, M., Geborek, P., Saxne, T., Bendtzen, K. (2007). Monitoring patients treated with anti-TNF-{alpha} biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46: 1828-1834 [Abstract] [Full Text]  
• Augustsson, J., Eksborg, S., Ernestam, S., Gullstrom, E., van Vollenhoven, R. (2007). Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 66: 1462-1466 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Sorrentino, D., Terrosu, G., Avellini, C., Maiero, S. (2007). Infliximab With Low-Dose Methotrexate for Prevention of Postsurgical Recurrence of Ileocolonic Crohn Disease. Arch Intern Med 167: 1804-1807 [Full Text]  
• Hanauer, S. B (2007). Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. Gut 56: 1181-1183 [Full Text]  
• Vermeire, S., Noman, M., Van Assche, G., Baert, F., D'Haens, G., Rutgeerts, P. (2007). Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56: 1226-1231 [Abstract] [Full Text]  
• Sandborn, W J, Hanauer, S B, Rutgeerts, P, Fedorak, R N, Lukas, M, MacIntosh, D G, Panaccione, R, Wolf, D, Kent, J D, Bittle, B, Li, J, Pollack, P F (2007). Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56: 1232-1239 [Abstract] [Full Text]  
• de Vries, M. K, Wolbink, G. J., Stapel, S. O, de Vrieze, H., van Denderen, J C., Dijkmans, B. A C, Aarden, L. A, van der Horst-Bruinsma, I. E (2007). Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66: 1252-1254 [Abstract] [Full Text]  
• Williams, J. V., Chen, Z., Cseke, G., Wright, D. W., Keefer, C. J., Tollefson, S. J., Hessell, A., Podsiad, A., Shepherd, B. E., Sanna, P. P., Burton, D. R., Crowe, J. E. Jr., Williamson, R. A. (2007). A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo. J. Virol. 81: 8315-8324 [Abstract] [Full Text]  
• Robinson, M. R., Korman, B. D., Korman, N. J. (2007). Combination Immunosuppressive Therapies: The Promise and the Peril. Arch Dermatol 143: 1053-1057 [Abstract] [Full Text]  
• Sands, B. E., Kaplan, G. G. (2007). The Role of TNF{alpha} in Ulcerative Colitis. J Clin Pharmacol 47: 930-941 [Abstract] [Full Text]  
• Bartelds, G. M, Wijbrandts, C. A, Nurmohamed, M. T, Stapel, S., Lems, W. F, Aarden, L., Dijkmans, B. A C, Tak, P. P., Wolbink, G. J. (2007). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66: 921-926 [Abstract] [Full Text]  
• Mannon, P. (2007). GAIN for Loss: Adalimumab for Infliximab-Refractory Crohn Disease. ANN INTERN MED 146: 888-890 [Full Text]  
• Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., Pollack, P. F. (2007). Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial. ANN INTERN MED 146: 829-838 [Abstract] [Full Text]  
• Farrell, R. A, Giovannoni, G. (2007). Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis. Mult Scler 13: 567-577 [Abstract]  
• Lofgren, J. A., Dhandapani, S., Pennucci, J. J., Abbott, C. M., Mytych, D. T., Kaliyaperumal, A., Swanson, S. J., Mullenix, M. C. (2007). Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab. J. Immunol. 178: 7467-7472 [Abstract] [Full Text]  
• D'Haens, G. (2007). Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 [Full Text]  
• Sfikakis, P. P., Markomichelakis, N., Alpsoy, E., Assaad-Khalil, S., Bodaghi, B., Gul, A., Ohno, S., Pipitone, N., Schirmer, M., Stanford, M., Wechsler, B., Zouboulis, C., Kaklamanis, P., Yazici, H. (2007). Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) 46: 736-741 [Full Text]  
• (2007). Abstracts. Gut 56: a1-a145 [Full Text]  
• Haibel, H, Brandt, H C, Song, I H, Brandt, A, Listing, J, Rudwaleit, M, Sieper, J (2007). No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66: 419-421 [Abstract] [Full Text]  
• van der Laken, C J, Voskuyl, A E, Roos, J C, Stigter van Walsum, M, de Groot, E R, Wolbink, G, Dijkmans, B A C, Aarden, L A (2007). Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 66: 253-256 [Abstract] [Full Text]  
• Edwards, C. J., Polosa, R. (2007). Study of Infliximab Treatment in Asthma. Am. J. Respir. Crit. Care Med. 175: 196-196 [Full Text]  
• Gaffo, A., Saag, K. G., Curtis, J. R. (2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63: 2451-2465 [Abstract] [Full Text]  
• Roos, J. C., Ostor, A. J., Okamoto, H., Dentener, M. A., Wouters, E. F.M., Scott, D.L., Kingsley, G.H. (2006). Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis. NEJM 355: 2046-2048 [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Klitgaard, J. L., Coljee, V. W., Andersen, P. S., Rasmussen, L. K., Nielsen, L. S., Haurum, J. S., Bregenholt, S. (2006). Reduced Susceptibility of Recombinant Polyclonal Antibodies to Inhibitory Anti-Variable Domain Antibody Responses. J. Immunol. 177: 3782-3790 [Abstract] [Full Text]  
• Reinisch, W, Hommes, D W, Van Assche, G, Colombel, J-F, Gendre, J-P, Oldenburg, B, Teml, A, Geboes, K, Ding, H, Zhang, L, Tang, M, Cheng, M, van Deventer, S J H, Rutgeerts, P, Pearce, T (2006). A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon {gamma} antibody, in patients with moderate to severe Crohn's disease. Gut 55: 1138-1144 [Abstract] [Full Text]  
• Gossec, L., Le Henanff, A., Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., Wendling, D., Lespessailles, E., Euller-Ziegler, L., Sibilia, J., Perdriger, A., Alexandre, C., Dougados, M. (2006). Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford) 45: 859-862 [Abstract] [Full Text]  
• Sidiropoulos, P I, Boumpas, D T (2006). Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.. Ann Rheum Dis 65: 701-703 [Full Text]  
• Finckh, A, Simard, J F, Gabay, C, Guerne, P-A, for the SCQM physicians, (2006). Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65: 746-752 [Abstract] [Full Text]  
• Travis, S P L, Stange, E F, Lemann, M, Oresland, T, Chowers, Y, Forbes, A, D'Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J, for the European Crohn's and Colitis Organisation, (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55: i16-i35 [Abstract] [Full Text]  
• Caprilli, R, Gassull, M A, Escher, J C, Moser, G, Munkholm, P, Forbes, A, Hommes, D W, Lochs, H, Angelucci, E, Cocco, A, Vucelic, B, Hildebrand, H, Kolacek, S, Riis, L, Lukas, M, de Franchis, R, Hamilton, M, Jantschek, G, Michetti, P, O'Morain, C, Anwar, M M, Freitas, J L, Mouzas, I A, Baert, F, Mitchell, R, Hawkey, C J, for the European Crohn's and Colitis Organisation, (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55: i36-i58 [Abstract] [Full Text]  
• Braun, J, Davis, J, Dougados, M, Sieper, J, van der Linden, S, van der Heijde, D, for the ASAS Working Group, (2006). First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65: 316-320 [Abstract] [Full Text]  
• ten Hacken, N., van der Vaart, H., Koeter, G., Kauffman, H., Postma, D. (2005). . Am. J. Respir. Crit. Care Med. 172: 1608-1608 [Full Text]  
• Heikkila, H., Ranki, A., Cajanus, S., Karvonen, S.-L. (2005). Infliximab Combined With Methotrexate as Long-term Treatment for Erythrodermic Psoriasis. Arch Dermatol 141: 1607-1610 [Full Text]  
• Keeley, K. A, Rivey, M. P, Allington, D. R (2005). Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. The Annals of Pharmacotherapy 39: 1833-1843 [Abstract] [Full Text]  
• Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y. (2005). Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats. J. Pharmacol. Exp. Ther. 315: 196-202 [Abstract] [Full Text]  
• Hauer, A.D., Uyttenhove, C., de Vos, P., Stroobant, V., Renauld, J.C., van Berkel, T.J.C., van Snick, J., Kuiper, J. (2005). Blockade of Interleukin-12 Function by Protein Vaccination Attenuates Atherosclerosis. Circulation 112: 1054-1062 [Abstract] [Full Text]  
• Francis, G. S., Rice, G. P.A., Alsop, J. C., for the PRISMS (Prevention of Relapses and Disabil, (2005). Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS. Neurology 65: 48-55 [Abstract] [Full Text]  
• Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Pare, P., McDonald, J. W.D., Dube, R., Cohen, A., Steinhart, A. H., Landau, S., Aguzzi, R. A., Fox, I. H., Vandervoort, M. K. (2005). Treatment of Ulcerative Colitis with a Humanized Antibody to the {alpha}4{beta}7 Integrin. NEJM 352: 2499-2507 [Abstract] [Full Text]  
• Vesga, L, Terdiman, J P, Mahadevan, U (2005). Adalimumab use in pregnancy. Gut 54: 890-890 [Full Text]  
• Rojas, J. R., Taylor, R. P., Cunningham, M. R., Rutkoski, T. J., Vennarini, J., Jang, H., Graham, M. A., Geboes, K., Rousselle, S. D., Wagner, C. L. (2005). Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys. J. Pharmacol. Exp. Ther. 313: 578-585 [Abstract] [Full Text]  
• Wolbink, G J, Voskuyl, A E, Lems, W F, de Groot, E, Nurmohamed, M T, Tak, P P, Dijkmans, B A C, Aarden, L (2005). Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 704-707 [Abstract] [Full Text]  
• Braun, J., Baraliakos, X., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Gromnica-Ihle, E., Kellner, H., Schneider, M., Sorensen, H., Zeidler, H., Sieper, J. (2005). Persistent clinical response to the anti-TNF-{alpha} antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44: 670-676 [Abstract] [Full Text]  
• Flendrie, M., Creemers, M. C. W., Welsing, P. M. J., van Riel, P. L. C. M. (2005). The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology (Oxford) 44: 472-478 [Abstract] [Full Text]  
• Rott, S., Mrowietz, U. (2005). Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ 330: 716-720 [Full Text]  
• Doty, J. D., Mazur, J. E., Judson, M. A. (2005). Treatment of Sarcoidosis With Infliximab. Chest 127: 1064-1071 [Abstract] [Full Text]  
• Mease, P J, Antoni, C E (2005). Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64: ii78-ii82 [Abstract] [Full Text]  
• Braun, J, Brandt, J, Listing, J, Zink, A, Alten, R, Burmester, G, Gromnica-Ihle, E, Kellner, H, Schneider, M, Sorensen, H, Zeidler, H, Sieper, J (2005). Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64: 229-234 [Abstract] [Full Text]  
• Ledingham, J., Deighton, C., on behalf of the British Society for Rheumatology, (2005). Update on the British Society for Rheumatology guidelines for prescribing TNF{alpha} blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44: 157-163 [Full Text]  
• Calin, A, Dijkmans, B A C, Emery, P, Hakala, M, Kalden, J, Leirisalo-Repo, M, Mola, E M, Salvarani, C, Sanmarti, R, Sany, J, Sibilia, J, Sieper, J, van der Linden, S, Veys, E, Appel, A M, Fatenejad, S (2004). Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63: 1594-1600 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J (2004). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 63: ii2-ii12 [Full Text]  
• Sandborn, W J, Feagan, B G, Radford-Smith, G, Kovacs, A, Enns, R, Innes, A, Patel, J (2004). CDP571, a humanised monoclonal antibody to tumour necrosis factor {alpha}, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485-1493 [Abstract] [Full Text]  
• Sandborn, W J, Faubion, W A (2004). Biologics in inflammatory bowel disease: how much progress have we made?. Gut 53: 1366-1373 [Full Text]  
• Genevay, S, Stingelin, S, Gabay, C (2004). Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann Rheum Dis 63: 1120-1123 [Abstract] [Full Text]  
• Braun, J., Sieper, J. (2004). Biological therapies in the spondyloarthritides--the current state. Rheumatology (Oxford) 43: 1072-1084 [Abstract] [Full Text]  
• Jabs, D. A., Gerard, H. C., Wei, Y., Campbell, A. L., Hudson, A. P., Akpek, E. K., Lee, B., Prendergast, R. A., Whittum-Hudson, J. A. (2004). Inflammatory Mediators in Autoimmune Lacrimal Gland Disease in MRL/Mpj Mice. IOVS 45: 2293-2298 [Abstract] [Full Text]  
• Olsen, N. J., Stein, C. M. (2004). New Drugs for Rheumatoid Arthritis. NEJM 350: 2167-2179 [Full Text]  
• Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., Rachmilewitz, D., Rutgeerts, P., Wild, G., Wolf, D. C., Marsters, P. A., Travers, S. B., Blank, M. A., van Deventer, S. J. (2004). Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. NEJM 350: 876-885 [Abstract] [Full Text]  
• Fiocchi, C. (2004). Closing Fistulas in Crohn's Disease -- Should the Accent Be on Maintenance or Safety?. NEJM 350: 934-936 [Full Text]  
• Sidiropoulos, P, Bertsias, G, Kritikos, H D, Kouroumali, H, Voudouris, K, Boumpas, D T (2004). Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 63: 144-148 [Abstract] [Full Text]  
• Verea, M. M, Del Pozo, J., Yebra-Pimentel, M T., Porta, A., Fonseca, E. (2004). Psoriasiform Eruption Induced by Infliximab. The Annals of Pharmacotherapy 38: 54-57 [Abstract] [Full Text]  
• Giovannoni, G. (2003). Strategies to treat and prevent the development of neutralizing anti-interferon-{beta} antibodies. Neurology 61: S13-17 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Dougados, M, Emery, P, Gibofsky, A, Kavenaugh, A F, Keystone, E C, Klareskog, L, Russell, A S, van de Putte, L B A, Weisman, M H (2003). Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 62: ii2-9 [Full Text]  
• Braun, J, Pham, T, Sieper, J, Davis, J, van der Linden, S., Dougados, M, van der Heijde, D (2003). International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62: 817-824 [Abstract] [Full Text]  
• Baeten, D, Kruithof, E, Van den Bosch, F, Van den Bossche, N, Herssens, A, Mielants, H, De Keyser, F, Veys, E M (2003). Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?. Ann Rheum Dis 62: 829-834 [Abstract] [Full Text]  
• Hanauer, S. B., Rutgeerts, P., Baert, F., Noman, M. (2003). Immunogenicity of Infliximab in Crohn's Disease. NEJM 348: 2155-2156 [Full Text]